Pediatric Adrenocortical Cancer (ACC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Pediatric Adrenocortical Cancer (ACC) Market Outlook

Thelansis’s “Pediatric Adrenocortical Cancer (ACC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pediatric Adrenocortical Cancer (ACC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Pediatric Adrenocortical Cancer (ACC) Overview

Pediatric Adrenocortical Cancer (ACC) is a rare neoplasm that affects the adrenal glands in children. The adrenal glands, located above the kidneys, produce hormones that regulate various physiological processes, including blood pressure, heart rate, and metabolism. Clinical presentation of pediatric ACC includes weight gain, hypertension, and changes in skin pigmentation. The genomic landscape of pediatric ACC is characterised by copy-neutral loss of heterozygosity on chromosomes 11 and 17, which is associated with germline TP53 pathogenic variants, insulin-like growth factor-2 overexpression, and somatic mutations in ATRX and CTNNB1. Li-Fraumeni Syndrome, an autosomal dominant familial cancer syndrome, is most commonly associated with pediatric ACC. Pediatric ACCs are more likely to be functional, often presenting with excess androgen production. The 5-year survival rate for pediatric ACC ranges from 30-70%, depending on disease presentation. The bimodal age distribution of pediatric ACC peaks under age five and after ten years, with 46% of diagnoses occurring in children under four years of age. The international TNM staging system classifies 44% of patients as stage I, 25% as stage II, 13% as stage III, and 17% as stage IV. The primary treatment for pediatric ACC is surgical resection, with adjuvant chemotherapy often employed depending on the results.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Pediatric Adrenocortical Cancer (ACC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034